FDA Approves First Oral PCSK9 Inhibitor for Cholesterol

The U.S. Food and Drug Administration has approved Lipfendra, a once-daily oral pill designed to lower LDL cholesterol ^[1].

This approval marks a shift in cardiovascular treatment by providing a convenient alternative to injectable drugs for patients who cannot tolerate statins or fail to reach target cholesterol levels with existing therapies ^[2].

Developed by Merck, Lipfendra (generic name enlicitide) is the first oral form of a PCSK9 inhibitor ^[1]. Previously, medications in this drug class required injections to block the protein that prevents the liver from removing LDL cholesterol from the blood ^[2]. The shift to a pill format removes the barrier of needle-based administration for millions of Americans ^[3].

Clinical trials indicate the medication is effective at reducing "bad" cholesterol. Data shows that Lipfendra can reduce LDL cholesterol by up to 60% ^[4]. This level of reduction is critical for reducing the risk of heart attack, and stroke in high-risk populations ^[3].

Medical professionals suggest the drug may be a game-changer for specific patient groups. Dr. Crandall said the medication provides a powerful new tool for those whose cholesterol remains high despite standard treatment ^[3]. Dr. Leah Croll said the drug's availability has an impact ^[1].

While statins remain the first line of defense for most patients, a significant number of people experience muscle pain or other side effects that make them intolerable ^[2]. Lipfendra offers these patients a way to manage their lipid levels without the side effects associated with statins, or the inconvenience of clinical visits for injections ^[4].